A large national survey finds that 57% of cannabis-using young adults in 23 U.S. states consume cannabis via two or more methods simultaneously, including smoking, vaping, and edibles. Recreational legalization, frequent use, and co-use of e-cigarettes and alcohol are all associated with higher odds of multi-modal consumption, though causality cannot be determined from this cross-sectional design.

Cannabis product markets have expanded dramatically in states with legal access, yet clinical screening still overwhelmingly defaults to asking patients whether they “smoke marijuana.” If the majority of young adult users are simultaneously inhaling, eating, and vaping cannabis, each method delivering different pharmacokinetic profiles with distinct onset times, durations, and dose uncertainties, then clinicians who ask about only one mode are systematically undercharacterizing their patients’ exposure. Understanding the scale and predictors of multi-modal use is essential for redesigning screening protocols, anticipating health risks, and shaping post-legalization public health surveillance.

The cannabis product landscape has diversified rapidly in the United States, particularly in states with recreational or medical legalization. Young adults aged 18 to 34 represent the demographic with the highest cannabis use prevalence, yet very little population-level data exists on how many of them are combining multiple administration methods, including smoking, vaping, consuming edibles, dabbing concentrates, and using other forms. This study drew on 2022 and 2023 waves of the Behavioral Risk Factor Surveillance System (BRFSS), a large telephone-based survey conducted across 23 states that included questions on cannabis use mode, to quantify the prevalence and predictors of multi-modal use among young adult current cannabis users.

Among 7,635 young adult cannabis users (representing approximately 7.5 million weighted individuals), 57% reported using cannabis via two or more methods in the past 30 days, with dual-mode and triple-mode use being the most common patterns. Weighted multivariable logistic regression identified several independent predictors of multi-modal use: sexual minority identity, 14 or more days of poor physical health, frequent cannabis use (especially 20 to 30 days per month), current e-cigarette use, and current alcohol use. Recreational cannabis legalization was significantly associated with higher odds of multi-modal use, while medical-only legalization was not. A difference-in-differences analysis examining states that newly adopted legalization between 2022 and 2023 found no statistically significant immediate effect, though this analysis was severely underpowered with only a single treated state per policy type. The authors acknowledge the study’s cross-sectional design precludes causal inference and call for longitudinal research to clarify directionality and clinical consequences.

Most Young Adult Cannabis Users Are Multi-Method Users: What That Means for Screening and Policy

If you ask a young adult patient whether they “smoke marijuana,” you may be missing more than half the story. In a nationally weighted survey of over 7,600 young adult cannabis users, 57% were using two or more different methods at the same time, and that proportion rises sharply among frequent users, sexual minority patients, and those living where cannabis is recreationally legal. This paper, drawn from the 2022 and 2023 BRFSS across 23 states, does something deceptively simple but genuinely important: it asks not just whether young adults use cannabis but how many ways they use it. The finding that multi-modal use is the statistical norm rather than an outlier behavior is the kind of descriptive result that should quietly reshape clinical practice. When we screen for cannabis exposure with a single question about smoking, we are doing the equivalent of asking about cigarette use to understand the full nicotine exposure landscape in an era of vapes, pouches, and lozenges. Each administration method carries distinct pharmacokinetics. Inhaled cannabis peaks rapidly and clears within hours; edibles produce delayed, prolonged, and often less predictable effects. Dabbing delivers extremely concentrated doses. A patient using all three is navigating a complex pharmacological environment, and a provider who only hears about one method has an incomplete picture.

What I find most valuable about this paper is its scale and its willingness to examine policy environment as a variable alongside individual-level predictors. The association between recreational legalization and multi-modal use is provocative, though it deserves careful interpretation. Cross-sectional data cannot tell us whether legalization caused diversification of use methods or whether states that legalized simply attracted or retained heavier, more experimentally inclined users. Think of it this way: finding that people in cities with more coffee shops drink more espresso does not mean the city’s coffee shop policy created the coffee culture. Both may reflect a third factor entirely. The same caution applies here. Similarly, the association between poor physical health and multi-modal use runs in both directions. A snapshot photo of people carrying umbrellas on a rainy day cannot tell you whether they brought umbrellas because it was raining or whether the umbrellas somehow caused the rain. This paper captures the snapshot competently but cannot resolve the directionality. The paper also classifies all multi-modal use as a single binary variable, which collapses clinically meaningful variation. A person who took one edible and one puff from a friend’s vaporizer once in a month counts identically to someone who smokes daily, dabs concentrates regularly, and eats edibles every evening. That binary flattening obscures nearly all the clinically relevant information about dose, frequency, and risk.

Despite these limitations, I would use this study in practice. To a patient, I would say: I want to understand not just whether you use cannabis but how, because each method affects your body differently, and many people use more than one way without realizing the cumulative effect. To a colleague, I would say: this confirms what we suspect anecdotally, and our screening tools need to catch up with mode-specific questions in standard intake. To a policymaker, I would say: recreational legalization appears to change not just whether people use cannabis but how, and our surveillance systems need to track method diversity, not just overall prevalence. This study does not prove that using cannabis via multiple routes is more harmful than single-method use, and it cannot tell us which came first, the health challenges or the multi-modal use. What it does establish, credibly and at scale, is that multi-modal use is already the statistical norm among young adult cannabis users in the United States, that it clusters with other high-risk behaviors, and that the policy environment actively shapes how people consume. When a behavior becomes normative in a population, our measurement tools need to be recalibrated to match reality. Asking young adults only about cannabis smoking is as outdated as asking about cigarette smoking to capture the full nicotine exposure landscape in the era of vaping and pouches.

This study sits early in the research arc for multi-modal cannabis use, occupying the descriptive epidemiology phase that must precede outcome-oriented research. It establishes prevalence with more statistical power and geographic breadth than prior convenience-sample studies, and it identifies candidate predictors that can guide the design of future longitudinal cohorts. Its position on the evidence hierarchy is observational and cross-sectional, meaning it generates hypotheses rather than testing them. No clinical consequences specific to multi-modal use, as opposed to high frequency or high quantity, have been established.

From a pharmacological standpoint, the clinical relevance lies in the distinct absorption, onset, and duration profiles of different administration methods. Inhaled cannabis delivers rapid-onset, short-duration effects with relatively predictable dose titration, while edibles produce delayed onset (30 to 90 minutes) with prolonged and less predictable effects. Dabbing delivers highly concentrated doses that can exceed typical inhalation exposures by a wide margin. A patient using all three methods simultaneously is navigating overlapping pharmacokinetic curves that increase the risk of accidental overconsumption, particularly with edibles. The one concrete recommendation supported by this evidence is straightforward: clinicians treating young adult patients should routinely ask about all modes of cannabis use, not just smoking, as part of standard substance use screening, particularly for patients who also report e-cigarette use or frequent alcohol consumption.

This is a cross-sectional secondary analysis of two waves of the BRFSS, a population-based telephone survey. It sits in the lower-middle tier of the evidence hierarchy, above case reports and expert opinion but below cohort studies, controlled trials, and systematic reviews. The single most important inference constraint is that no causal, temporal, or directional conclusions can be drawn from this design. All identified associations, including the link between recreational legalization and multi-modal use, could be explained by unmeasured confounders or reverse causation.

The 57% multi-modal prevalence aligns with the lower bound of the 57 to 88% range reported in prior smaller studies of young adult cannabis users, providing large-sample confirmation that multi-modal use is the dominant consumption pattern in this age group, not an outlier finding driven by convenience sampling. The null finding for medical cannabis legalization is consistent with a prior meta-analysis showing that medical legalization has minimal effect on cannabis use among young adults. The association between recreational legalization and greater method diversification extends findings from earlier studies that linked recreational legalization to increased past-month use frequency and intensity, adding mode diversification as another dimension of use that appears to shift in legal market environments. This study’s contribution is primarily one of scale and breadth, confirming prior smaller findings with a nationally representative weighted sample.

The most consequential analytic choice was defining multi-modal use as a binary variable (two or more methods versus one). This collapses substantial variation in intensity and risk. A person who tried one edible and smoked once is classified identically to a daily user of three methods. An ordinal or count-based outcome (number of methods), or an analysis stratified by specific mode combinations, would likely have revealed meaningful heterogeneity that the binary definition obscures. Additionally, the difference-in-differences analysis, while conceptually sound, used only a single treated state per policy change, rendering it severely underpowered. With more states transitioning between survey waves, this approach could have provided much stronger quasi-causal evidence. Adjusting for cannabis use frequency as a covariate is also debatable, since frequency may mediate the relationship between legalization and multi-modal use rather than confound it, and including it in the model may attenuate the policy effect estimate.

The most likely overinterpretation is reading the recreational legalization association as proof that legalization causes young adults to use cannabis in more ways. This exceeds what the evidence supports. States that adopted recreational legalization may differ from non-adopting states in population composition, cultural attitudes, market maturity, and unmeasured confounders that independently influence how people consume cannabis. The cross-sectional design cannot separate these influences from a policy-driven effect. A second common misreading is interpreting the association between poor physical health and multi-modal use as evidence that multi-modal use harms health. The direction is entirely ambiguous: individuals with chronic pain or other conditions may seek cannabis through multiple routes for symptom management, or heavy multi-method use may contribute to health problems. This study measured health status as a predictor variable, not as an outcome.

This study provides the largest nationally weighted estimate to date confirming that multi-modal cannabis use is the dominant pattern among U.S. young adult users, not a niche behavior. It identifies plausible predictors, including recreational legalization, sexual minority identity, and polysubstance use, but cannot establish causality, directionality, or clinical consequences. For practice right now, the clearest implication is that clinicians should ask about all methods of cannabis use during screening, not just smoking, because a single-method question systematically mischaracterizes the majority of young adult users.

What does “multi-modal cannabis use” mean?

Multi-modal cannabis use means using cannabis through two or more different methods within the same time period, such as both smoking and eating edibles, or vaping and dabbing concentrates. This study counted five categories: smoking, vaping, edibles, dabbing, and other methods. If a person reported using any two or more of these in the past 30 days, they were classified as a multi-modal user.

Is using cannabis in multiple ways more dangerous than using just one method?

This study did not measure health outcomes, so it cannot answer that question directly. Different methods do deliver cannabis differently to the body, with different onset times, durations, and dose profiles, which could theoretically increase the risk of accidental overconsumption or cumulative exposure. However, research specifically comparing health outcomes between multi-modal and single-modal users at the same overall frequency and quantity has not yet been done.

Does recreational legalization cause people to use cannabis in more ways?

The study found an association between living in a state with recreational cannabis legalization and higher odds of multi-modal use, but it cannot prove causation. States that legalize recreational cannabis may differ from other states in many ways, including the variety of products available, cultural attitudes, and population demographics. Legalization likely increases access to diverse products, but other factors may also contribute to the observed pattern.

Should I tell my doctor about all the different ways I use cannabis?

Yes. Each method of cannabis use affects your body differently, and your doctor needs a complete picture to provide appropriate care. Smoking and vaping have respiratory implications; edibles carry risk of delayed overconsumption; and dabbing involves very high concentrations. Sharing the full picture with your provider helps them assess your health more accurately and offer relevant guidance.

Have thoughts on this? Share it: